GlaxoSmithKline (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a report released on Friday.

Other research analysts also recently issued reports about the company. Berenberg Bank reissued a buy rating and issued a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a research note on Wednesday, December 13th. UBS set a GBX 1,550 ($21.41) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Wednesday, December 13th. Jefferies Group reissued a buy rating and issued a GBX 1,500 ($20.72) price objective on shares of GlaxoSmithKline in a research note on Tuesday, January 16th. Liberum Capital reissued a buy rating and issued a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a research note on Monday, January 15th. Finally, Goldman Sachs set a GBX 1,775 ($24.52) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 1,529.55 ($21.13).

How to Become a New Pot Stock Millionaire

GlaxoSmithKline (GSK) traded up GBX 41.80 ($0.58) during midday trading on Friday, reaching GBX 1,315.60 ($18.18). The company had a trading volume of 23,227,458 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.07) and a 1 year high of GBX 1,724.50 ($23.83). The firm has a market cap of $65,630.00 and a P/E ratio of 2,482.26.

The business also recently announced a dividend, which will be paid on Thursday, April 12th. Shareholders of record on Thursday, February 22nd will be paid a GBX 23 ($0.32) dividend. The ex-dividend date is Thursday, February 22nd. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. This represents a dividend yield of 1.78%.

In other GlaxoSmithKline news, insider Sir Roy Anderson acquired 562 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Also, insider Victoria Whyte sold 5,199 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of GBX 1,295 ($17.89), for a total value of £67,327.05 ($93,018.86). Over the last ninety days, insiders acquired 591 shares of company stock valued at $756,678 and sold 23,765 shares valued at $31,152,709.

WARNING: “GlaxoSmithKline (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3295994/glaxosmithkline-gsk-receives-neutral-rating-from-jpmorgan-chase-co-2.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Westwood Holdings Group  Issues Quarterly  Earnings Results
Westwood Holdings Group Issues Quarterly Earnings Results
NewMarket  Releases  Earnings Results, Misses Expectations By $0.46 EPS
NewMarket Releases Earnings Results, Misses Expectations By $0.46 EPS
Purple Innovation  Receiving Positive Media Coverage, Analysis Shows
Purple Innovation Receiving Positive Media Coverage, Analysis Shows
Traders Buy Shares of SPDR Gold Shares  on Weakness
Traders Buy Shares of SPDR Gold Shares on Weakness
Investors Buy Visa  on Weakness
Investors Buy Visa on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF  on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF on Weakness


© 2006-2018 Ticker Report. Google+.